Notation to File

NOTE TO THE FILE

SERIAL NUMBER:            88312155

DATE:                                05/06/2019

NAME:                               jbaker

NOTE:         

Searched:                                                             
     Google                            
     Lexis/Nexis                       
     OneLook
     Wikipedia
     Acronym Finder                         Protest evidence reviewed
     Other:

Checked:                                                             
     Geographic significance          
     Surname                          
     Translation
     ID with ID/CLASS mailbox

     Checked list of approved Canadian attorneys and agents

Discussed file with
Attorney/Applicant via:
        phone                               Left message with
    X   email                               Attorney/Applicant

     Requested Law Library search           Issued Examiner’s Amendment
     for:                                   and entered changes in TRADEUPS

        PRINT        DO NOT PRINT           Added design code in TRADEUPS
     Description of the mark
     Translation statement                  Re-imaged standard character
                                            drawing
     Negative translation statement             
     Consent of living individual           Contacted TM MADRID ID/CLASS
                                            about misclassified definite ID
     Changed TRADEUPS to:

     OTHER:

Jordan,

 

The changes you have suggested for Trademark App. Nos. 88312155, 88331577, and 88332276, as detailed below are acceptable. Please let me know if there is anything else you need.

 

Thanks.

 

----Randy

 

 

Randy Berholtz, MBA/JD

Executive Vice President, Corporate 

Development and General Counsel 

Innovus Pharmaceuticals, Inc. 

8845 Rehco Rd

San Diego, CA 92121 

Office: 858-249-7873

Cell:  858-205-5091

Fax: 858249-7879

E-mail: rberholtz@innovuspharma.com 

 

 

Disclaimer: This message is confidential and proprietary to Innnovus Pharmaceuticals, Inc. or to its wholly-owned subsidiary Fastrack Pharmaceuticals, Inc and Semprae Labs. If you are not the intended recipient please either destroy this e-mail immediately and don't rely on its contents or return it immediately to the person named above. Thank you.

 

 

 

From: Baker, Jordan <jordan.baker@USPTO.GOV>
Sent: Friday, May 3, 2019 12:21 PM
To: Randy Berholtz <rberholtz@innovuspharma.com>
Cc: Jake Siciliano <JSiciliano@innovuspharma.com>; Vincent Arendain <VArendain@innovuspharma.com>
Subject: U.S. Trademark App. Nos. 88312155, 88331577, and 88332276 - Examiner Amendments requested

 

Dear Mr. Berholtz,

 

I am the trademark examining attorney reviewing the following applications. I believe slight amendments are required as noted below. Please confirm that they changes are acceptable and I can enter them by Examiner’s Amendment and approve them for publication.

 

Serial No. 88312155 – SEMPRAE LABORATORIES

Disclaimer of “LABORATORIES”

 

Serial No. 88331577 – INNOVUS PHARMA

Disclaimer of “PHARMA”

 

Serial No. 88332276 - MUSCLOPAN

ID amendment in Class 5: “Topical medical solutions to treat a variety of skin and muscular conditions by improving tissue function of both intact and damaged skin, the underlying capillary bed, and associated muscular tissues; Homeopathic medications and homeopathic pharmaceuticals for use in the treatment cramps and pain in the leg, foot, arm, hands, and neck”

 

Kind regards,

 

Jordan A. Baker

Trademark Examining Attorney

Lead Attorney for Proof of Use Audit Program

U.S. Patent and Trademark Office

Law Office 124

571-272-8844

jordan.baker@uspto.gov